NR4A1 and triple-negative breast carcinoma: Our data provide additional support for selection on nonanthracycline regimens in women with early stage breast cancer unless the projected benefit for anthracycline regimens is clearly associated with improved outcomes (for example, women with triple-negative breast cancer or those with hormone receptor–positive breast cancer with 4 or more positive nodes).